• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 2:41:57 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CARA alert in real time by email
    SC 13G 1 firstmanhattan-cara123120.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Cara Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001

    (Title of Class of Securities)

     

    140755109

    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  140755109
     SCHEDULE 13G
    Page 2 of 6 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    First Manhattan Co.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    New York
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    3,099,096
    6
    SHARED VOTING POWER
     
    113,700
    7
    SOLE DISPOSITIVE POWER
     
    3,099,096
    8
    SHARED DISPOSITIVE POWER
     
    113,700
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,212,796
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.45%
    12
    TYPE OF REPORTING PERSON
     
    BD, IA

     


     

     

    CUSIP No. 140755109
     SCHEDULE 13G
    Page 3 of 6 Pages

     

    Item 1.(a) Name of Issuer

    Cara Therapeutics, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    4 Stamford Plaza

    107 Elm Street, 9th Floor

    Stamford, Connecticut 06902

    Item 2.(a) Name of Person Filing:

    First Manhattan Co.

     

    Item 2.(b) Address of Principal Business Office:

    399 Park Avenue

    New York, NY 10022

     

    Item 2.(c) Citizenship:

    New York

      

    Item 2.(d) Title of Class of Securities

    Common Stock, par value $0.0001

     

    Item 2.(e) CUSIP No.:

    140755109

     

    CUSIP No.  140755109
     SCHEDULE 13G
    Page 4 of 6 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) x Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 140755109
     SCHEDULE 13G
    Page 5 of 6 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: 3,212,796

    (b) Percent of class: 6.45%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 3,099,096

    (ii) Shared power to vote or to direct the vote: 113,700

    (iii) Sole power to dispose or to direct the disposition of: 3,099,096

    (iv) Shared power to dispose or to direct the disposition of: 113,700

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 140755109
     SCHEDULE 13G
    Page 6 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2021

     

     

     

     

    First Manhattan Co.

           
      By:  /s/ Thomas Kennedy
        Thomas Kennedy, Chief Compliance Officer
           
           

     

    Get the next $CARA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CARA

    DatePrice TargetRatingAnalyst
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    6/13/2024Buy → Hold
    Needham
    6/13/2024Buy → Neutral
    H.C. Wainwright
    3/8/2023$13.00 → $6.00Neutral → Underperform
    BofA Securities
    3/8/2022$17.00 → $20.00Neutral → Overweight
    JP Morgan
    11/1/2021$33.00Buy
    Canaccord Genuity
    8/24/2021$33.00 → $35.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CARA
    SEC Filings

    See more
    • Cara Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure, Other Events

      8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

      4/15/25 4:06:29 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cara Therapeutics, Inc. (0001346830) (Filer)

      4/11/25 4:16:03 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Cara Therapeutics, Inc. (0001346830) (Filer)

      4/1/25 4:30:32 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    Financials

    Live finance-specific insights

    See more
    • Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

      Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

      12/18/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

      –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio

      3/4/24 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

      STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical co

      2/12/24 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cara Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously

      6/13/24 7:05:24 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously

      6/13/24 7:05:04 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics downgraded by Needham

      Needham downgraded Cara Therapeutics from Buy to Hold

      6/13/24 7:04:33 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Cara Therapeutics Inc.

      SC 13D - Cara Therapeutics, Inc. (0001346830) (Subject)

      10/30/24 4:21:50 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

      SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

      2/13/24 6:50:36 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

      SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

      2/13/24 5:01:02 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    Leadership Updates

    Live Leadership Updates

    See more
    • Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

      STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards. "We are pleased to welcome Helen to the Cara board," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "We look forward to leveraging her

      8/3/23 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Announces Appointment of Christopher Posner as New Independent Director

      24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.

      11/29/22 7:30:00 AM ET
      $CARA
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

      STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors. Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc. "We are very pleased to welcome Lisa to our board of directors," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "Her extensive clinical development and pharmacology expertise will be of great value as we continue executing o

      11/3/22 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

      STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that its Board of Directors (the "Board") has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara's common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on Wednesday, April 16, 2025 under the new name "Tvardi Therapeutics, Inc." and under the new symbol "TVRD" following the anticipated closing of the merger (the "Merger") with Tvard Therapeutics, Inc. ("Tvardi"), with a new CUSIP number 140755 307. The reverse stock split was approved by Cara's stockholders at Cara's special

      4/14/25 11:50:29 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

      STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Tuesday, December 31, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "CARA" with the new CUSIP number, 1

      12/27/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

      Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

      12/18/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:20 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Research & Development Larson Jeffrey Leroy

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:32 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:30 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

      Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

      8/24/21 12:36:58 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care